Skip to main content
Log in

Intramuscular calcitriol for uraemic children with severe hyperparathyroidism and hypercalcaemia

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The effect of intramuscular calcitriol was evaluated in five children (aged 1–16 years) with severe chronic renal failure and hyperparathyroidism [range of intact parathyroid hormone (PTH) 400–1,200 pg/ml]. All five children had been on oral calcitriol or 1α-hydroxyvitamin D3 treatment (5–20 ng/kg per day), but an adequate, efficacious dosage could not be achieved since any attempt of increasing the dosage resulted in severe hypercalcaemia (>2.9 mmol/l). Intramuscular calcitriol was given three times weekly for 5 months at an initial dosage of 65–70 ng/kg to all but one patient who received 100 ng/kg. In the first three patients, treatment resulted in an 86%–98% fall in serum PTH compared with baseline levels and serum calcium never exceeded 2.65 mmol/l, except for one episode of hypercalcaemia in one patient. In the last two patients, serum calcium rose above normal limits, thus calcitriol had to be discontinued several times and then restarted at a lower dosage (40 ng/kg); PTH fell by 61% and 73%, respectively, compared with basal values. All patients had very low pre-treatment levels of serum 1,25-dihydroxyvitamin D3 (5–15 pg/ml) which were normalized (35–56 pg/ml) by the intramuscular calcitrioltreatment. Serum phosphorus and magnesium did not vary in any of the five patients. No side effects were observed at the injection site. Intramuscular calcitriol seems a useful therapeutic option for patients with severe hyperparathyroidism associated with a high serum calcium level when treated with conventional oral calcitriol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Malluche HH, Faugere FC (1989) Renal osteodystrophy. N Engl J Med 321: 317–318

    Google Scholar 

  2. Mehls O, Salusky IB (1987) Recent advances and controversies in childhood renal osteodystrophy. Pediatr Nephrol 1: 212–223

    Google Scholar 

  3. Brown EM, Brennan MF, Hurwitz S, Windeck R, Marx SJ, Spiegel AM, Koehler JO, Gardner DJ, Aurbach GD (1978) Dispersed cells prepared from human parathyroid glands: distinct calcium sensitivity of adenomas vs primary hyperplasia. J Clin Endocrinol Metab 6: 267–275

    Google Scholar 

  4. Malluche H, Faugere MC (1990) Effects of 1.25 (OH)2 D3 administration on bone in patients with renal failure. Kidney Int 38: S48-S53

    Google Scholar 

  5. Slatopolsky E, Lopez-Hilker S, Delmez J, Dusso A, Brown A, Martin KJ (1990) The parathyroid-calcitriol axis in health and chronic failure. Kidney Int 38: S41-S47

    Google Scholar 

  6. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B (1988) Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 34: 840–844

    Google Scholar 

  7. Napoli JL, Premanik BC, Royal PM, Reinhardt TA, Horst RL (1983) Intestinal synthesis of 24-keto-1.25 dihydroxyvitamin D3: a metabolite formed in vivo with high affinity for vitamin D cytosolic receptors. J Biol Chem 258: 9100–9107

    Google Scholar 

  8. Coburn JW (1990) Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38: S54-S61

    Google Scholar 

  9. Brickman AS, Coburn JW, Friedman GR, Okamura WH, Massry GW, Norman AW (1976) Comparison of effects of 1-alfa-hydroxyvitamin D3 and 1.25-dihydroxyvitamin D3 in man. J Clin Invest 57: 1540–1547

    Google Scholar 

  10. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136–2143

    Google Scholar 

  11. Andress DL, Norris KC, Coburn JW, Slatopolsky E, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274–279

    Google Scholar 

  12. Delmez J, Tindira PG, Grooms P, Dusso A, Windus DW, Slatopolsky E (1989) Parathyroid hormone suppression by intravenous 1.25-dihydroxyvitamin D. J Clin Invest 83: 1349–1355

    Google Scholar 

  13. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F (1991) The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2: 1014–1020

    Google Scholar 

  14. Trachtman H, Gauthier B (1987) Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal insufficiency. J Pediatr 110: 966–970

    Google Scholar 

  15. Cantley LK, Russell J, Lettieri D, Sherwood LM (1985) 1.25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from parathyroid cells in tissue culture. Endocrinology 117: 2114–2119

    Google Scholar 

  16. Brumbaugh PF, Hughes MR, Hausler MR (1975) Cytoplasmic and nuclear binding components for 1.25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci USA 72: 4871–4875

    Google Scholar 

  17. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo by the rat. J Clin Invest 78: 1296–1301

    Google Scholar 

  18. Russell J, Lettieri D, Sherwood LM (1986) Suppression by 1.25 (OH)2 D3 of transcription of the parathyroid hormone gene. Endocrinology 119: 2864–2866

    Google Scholar 

  19. Korkor AB (1987) Reduced binding of 1.25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1573–1577

    Google Scholar 

  20. Malluche HH, Goldstein DA, Maluche SG (1980) Effects of 6 months therapy with 1.25 (OH)2 D3 on bone disease of dialysis patients. Contrib Nephrol 18: 98–104

    Google Scholar 

  21. Klaus G, Schaefer F, Soergel M, Ritz E, Mehls O (19917 Oral calcitriol pulse therapy is effective and safe for treatment of secondary hyperparathyroidism. Pediatr Nephrol 5: C24

    Google Scholar 

  22. Dall'Amico R, Montini G, Murer G, Maiocco F, Andretta B, Luisetto G, Zacchello G (1991) Subcutaneous calcitriol administration in CAPD children: absorption kinetic study. J Am Soc Nephrol 2: 634

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Claris-Appiani, A., Ardissino, G.L., Tischer, M.C. et al. Intramuscular calcitriol for uraemic children with severe hyperparathyroidism and hypercalcaemia. Pediatr Nephrol 8, 719–723 (1994). https://doi.org/10.1007/BF00869100

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00869100

Key words

Navigation